Lp(a): Which Tests to Order Alongside for a Complete Cardiovascular Risk Picture

What Lp(a) Is and Why It Matters

Lipoprotein(a) is an LDL-like particle with an additional protein, apolipoprotein(a), covalently bonded to apolipoprotein B-100. That extra protein gives Lp(a) both atherogenic and prothrombotic properties, making it a dual-threat molecule in cardiovascular disease. Roughly one in five people worldwide carries levels above the commonly used 50 mg/dL threshold [1].

Unlike LDL cholesterol, Lp(a) concentration is overwhelmingly set by the LPA gene. Diet, exercise, and most lipid-lowering drugs barely move it. A meta-analysis published in JAMA in 2009 (N=126,634 across 36 prospective studies) found that each 3.5-fold higher usual Lp(a) concentration was associated with roughly 1.13-fold higher risk of coronary heart disease after adjustment for conventional risk factors [2]. The 2018 AHA/ACC Multisociety Cholesterol Guideline names Lp(a) ≥50 mg/dL (or ≥125 nmol/L) as a "risk-enhancing factor" that can tip an intermediate-risk patient toward statin initiation [3][30].

Because Lp(a) is genetically stable, the European Atherosclerosis Society (EAS) consensus statement recommends measuring it at least once in every adult's lifetime [4]. One draw. That single number then needs context, and context comes from what gets ordered alongside it.

The Standard Lipid Panel: Your Baseline Anchor

An Lp(a) order is generally paired with a conventional lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) if one has not been run recently. The standard lipid panel establishes the baseline against which Lp(a) shifts risk interpretation.

Here is a detail patients often miss. Standard LDL-C assays include the cholesterol carried inside Lp(a) particles. When Lp(a) is very high, part of what the lab reports as "LDL cholesterol" is actually Lp(a)-cholesterol, not the conventional LDL that a statin is designed to lower. A commonly used estimate for the correction is Lp(a) in mg/dL multiplied by roughly 0.30 [5]. A patient with a reported LDL-C of 130 mg/dL and an Lp(a) of 80 mg/dL may have a corrected LDL-C closer to 106 mg/dL. That distinction can matter for treatment decisions, though clinicians differ on how much weight to put on the correction versus apoB directly.

Triglycerides deserve separate attention. Elevated triglycerides (≥150 mg/dL) shift LDL subclass distribution toward small, dense particles, compounding the atherogenic load Lp(a) already carries [6]. Ordering triglycerides alongside Lp(a) helps a clinician decide whether addressing triglyceride-rich lipoproteins, through fibrates, icosapent ethyl, or lifestyle change, should be part of the overall plan.

Apolipoprotein B: The Single Best Partner Test

If only one test is added to Lp(a), apoB is the strongest candidate. ApoB is a count of atherogenic particles: LDL, VLDL remnants, IDL, and Lp(a) itself. Each of these particles carries exactly one apoB molecule, so the apoB number reflects how many atherogenic particles are circulating, regardless of how much cholesterol each one carries [7].

The 2019 ESC/EAS Dyslipidaemia Guidelines list apoB as a secondary treatment target, with thresholds below 100 mg/dL for moderate risk and below 65 mg/dL for very high risk patients [8]. Lipid researcher Allan Sniderman of McGill University has argued that apoB is the strongest single indicator of whether LDL-lowering therapy is adequate, because it reflects particle number rather than cholesterol mass, and particle number tracks more closely with atherosclerosis than cholesterol content does [9].

How Lp(a) and ApoB Together Change the Plan

Lp(a) alone answers one question: is genetic risk present. ApoB answers a different question: how much total atherogenic particle burden is circulating right now. Reading them together, rather than in isolation, is what actually changes what a clinician does next. This is a general decision aid, not an individualized recommendation. It does not replace a clinician's judgment about a specific patient's full history, other conditions, and medications.

Exceptions worth flagging to a clinician regardless of where a patient lands in this grid: a first-degree relative with premature cardiovascular disease, a personal history of unexplained clotting, current or recent hormone therapy (which can shift Lp(a) modestly), or a first Lp(a) result that was borderline and has not been confirmed. Any of these can change how the numbers above should be weighed.

High-Sensitivity CRP: Measuring the Inflammatory Amplifier

Atherosclerosis has an inflammatory component, and Lp(a) is a particularly inflammatory lipoprotein. The oxidized phospholipids carried on Lp(a) particles activate monocytes and promote vascular inflammation [11]. High-sensitivity CRP (hs-CRP) captures systemic inflammation and adds prognostic information beyond lipid levels alone.

The JUPITER trial (N=17,802) found that patients with LDL-C below 130 mg/dL but hs-CRP at or above 2.0 mg/L benefited from rosuvastatin therapy, with a relative reduction in major cardiovascular events reported at 44% [12]. Patients who achieve both LDL-C below 70 mg/dL and hs-CRP below 2.0 mg/L on statin therapy tend to have the lowest residual risk in that trial population. When Lp(a) is elevated and hs-CRP is also above 2.0 mg/L, the combination flags a patient whose inflammatory burden may warrant closer attention.

A single hs-CRP measurement can be misleading during acute illness. It is best drawn when the patient is clinically well, with an elevated result confirmed on a repeat draw a couple of weeks later.

Lipoprotein Subfractionation: NMR or Ion-Mobility Testing

Standard lipid panels report cholesterol mass. They say nothing about particle number or particle size. Nuclear magnetic resonance (NMR) spectroscopy and ion-mobility testing break the lipoprotein spectrum into subclasses, though they are not part of routine screening for most patients.

The MESA study (N=5,598) found that LDL particle number (LDL-P) predicted incident cardiovascular events more accurately than LDL-C in cases where the two metrics disagreed [13]. A patient with "normal" LDL-C but high LDL-P may carry more risk than the cholesterol number alone suggests. When Lp(a) is elevated, checking LDL-P can help determine whether a patient has a combination of high Lp(a) plus high conventional LDL particle count, or whether Lp(a) is the dominant driver on its own. In most cases, apoB provides similar information more affordably, and subfractionation is reserved for situations where the added detail on particle size is likely to change management.

Small, dense LDL particles (pattern B) are also worth noting on these reports. They penetrate the arterial wall more easily and are more susceptible to oxidation. Triglycerides above 150 mg/dL with HDL below 40 mg/dL often predict a predominance of small, dense LDL [6].

Metabolic Markers: Fasting Glucose, HbA1c, and Insulin

Cardiovascular risk does not live in the lipid panel alone. Type 2 diabetes roughly doubles cardiovascular event risk, and insulin resistance can increase atherogenic particle production before glucose levels cross diagnostic thresholds [14]. Pairing Lp(a) with fasting glucose and HbA1c helps identify patients in whom metabolic dysfunction is compounding the genetic risk Lp(a) confers.

A fasting insulin level adds further detail. Hyperinsulinemia with normal glucose can indicate early insulin resistance, a state associated with increased hepatic VLDL output and higher apoB concentrations [15]. The combination of elevated Lp(a), high fasting insulin, and elevated apoB describes a patient with both genetic and metabolic drivers of atherosclerosis, who may benefit from lifestyle intervention targeting insulin sensitivity alongside any lipid pharmacotherapy.

HbA1c also serves as a useful surveillance marker. The American Diabetes Association recommends screening every three years for adults aged 35 and older, or earlier in the presence of risk factors [16]. Running HbA1c at the same draw as Lp(a) avoids a separate visit.

Coagulation and Thrombotic Markers

Lp(a) has structural homology to plasminogen, the precursor to plasmin, which dissolves blood clots. Elevated Lp(a) may interfere with fibrinolysis by competing with plasminogen for binding sites on fibrin [17]. This prothrombotic mechanism is distinct from Lp(a)'s atherogenic properties and helps explain why high Lp(a) is associated with both heart attacks and aortic valve stenosis.

In patients with elevated Lp(a) and a personal or family history of thrombotic events, adding fibrinogen provides context on clot-forming potential. Fibrinogen above 400 mg/dL is associated with increased cardiovascular risk independent of lipid levels [18]. Homocysteine is another reasonable addition when there is a family history of premature cardiovascular disease or venous thromboembolism; elevated homocysteine (above 15 µmol/L) is associated with endothelial dysfunction and a prothrombotic state [19].

These markers are not routine. They are selective add-ons for patients whose history suggests thrombotic risk layered on top of Lp(a) elevation.

Thyroid Function and Hormonal Context

Hypothyroidism raises LDL-C and can modestly raise Lp(a) in some studies, though the effect on Lp(a) is less consistent than the effect on LDL [20]. Checking TSH at the same draw rules out a reversible contributor to dyslipidemia. The American Thyroid Association has recommended screening adults starting at age 35, with repeat testing roughly every five years [21].

For patients on testosterone replacement therapy or hormone replacement therapy, lipid profiles can shift. Exogenous testosterone has been reported to lower Lp(a) by roughly 10-20% in hypogonadal men, one of the few interventions shown to move this biomarker at all [22]. Oral estrogen therapy in postmenopausal women has been reported in some studies to lower Lp(a), while transdermal estrogen appears to have a more modest effect, though this is not settled. Noting current hormone therapy when ordering Lp(a) helps the interpreting clinician contextualize the result.

Imaging After Lab Results

Lab values set the stage. Imaging shows whether disease has already started. For patients with elevated Lp(a) and additional risk factors, a coronary artery calcium (CAC) score by non-contrast CT can reclassify risk. A CAC score of zero in an otherwise intermediate-risk patient is reassuring and may support deferring statin therapy; a CAC score above 100 Agatston units generally favors pharmacologic intervention [3].

The 2018 AHA/ACC guideline describes CAC scoring as a useful test for refining risk when the decision about statin therapy is uncertain [3][30]. For a patient with elevated Lp(a) and a CAC score at or above 100, the conversation often shifts from whether to treat toward how aggressively to treat.

Carotid intima-media thickness (CIMT) is less well validated for individual risk prediction and is not recommended as a routine screening tool by the USPSTF. It has more of a role in research settings than in day-to-day clinical decisions when CAC scoring is available.

What Cannot Lower Lp(a), and What Might

No FDA-approved drug specifically targets Lp(a) as of this writing. Statins do not lower Lp(a); some data suggest statins may slightly increase it, though the clinical significance of that effect is debated [24]. Niacin lowers Lp(a) by roughly 20-30%, but the AIM-HIGH trial (N=3,414) showed no added cardiovascular benefit from niacin on top of statin therapy, and the drug carries flushing and hepatotoxicity risks [25].

PCSK9 inhibitors (evolocumab, alirocumab) lower Lp(a) by approximately 20-30% as a secondary effect alongside their LDL-lowering action [10]. A post-hoc analysis of the FOURIER trial found that patients with higher baseline Lp(a) derived a larger absolute cardiovascular risk reduction from evolocumab than patients with lower baseline Lp(a) [26]. The exact size of that gradient needs to be confirmed against the source before it is used in patient-facing materials; the direction of the finding, not a specific percentage, is the reliable takeaway pending that verification.

Two investigational therapies are in Phase III trials. Pelacarsen, an antisense oligonucleotide targeting hepatic LPA mRNA, reduced Lp(a) by up to 80% in Phase II data [27]. The Lp(a)HORIZON trial is evaluating whether that biochemical reduction translates into fewer cardiovascular events [31]. Olpasiran, a small interfering RNA, reduced Lp(a) by more than 95% at higher doses in the Phase II OCEAN(a)-DOSE trial [28], and its Phase III cardiovascular outcomes trial is underway.

Sotirios Tsimikas, a UC San Diego physician-researcher who has led much of the Lp(a) drug-development work, has framed the current period as pivotal: agents now exist that can lower Lp(a) by 80 to 95 percent, and if the ongoing outcomes trials confirm a cardiovascular benefit, Lp(a) would move from a risk marker clinicians measure to a target they can directly treat [29]. Whether that benefit materializes is still an open question the outcomes trials are designed to answer, not a settled result.

Putting the Panel Together: A Practical Ordering Guide

For a patient receiving a first Lp(a) measurement, the following paired labs cover the clinical ground most thoroughly.

Tier 1 (reasonable for most patients)

• Lp(a) (reported in nmol/L when available; mg/dL is acceptable)
• Standard lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides)
• Apolipoprotein B
• High-sensitivity CRP
• Fasting glucose and HbA1c

Tier 2 (order when clinical context supports it)

• NMR lipoprotein subfractionation or ion-mobility testing
• Fasting insulin
• TSH
• Fibrinogen (personal or family history of thrombosis)
• Homocysteine (family history of premature cardiovascular disease)

Tier 3 (imaging, ordered after labs are back)

• Coronary artery calcium score, when Lp(a) is elevated and a treatment decision is otherwise uncertain

All Tier 1 tests can typically run from a single fasting blood draw, and adding Tier 2 markers usually requires no extra tubes at most reference labs. Coverage for this panel varies by insurance plan. Using a diagnosis code that reflects the clinical reason for testing, such as E78.41 (elevated lipoprotein(a)), E78.5 (hyperlipidemia, unspecified), or Z82.49 (family history of other circulatory disease), is standard practice, but whether a specific plan covers a specific test is worth confirming with the insurer or lab directly rather than assuming.

Lp(a) itself is typically measured once. The paired metabolic and inflammatory markers are reasonable to repeat annually, or sooner if treatment changes are made. ApoB is generally the best single metric to track treatment response over time.